NYLIM
UTHR icon

New York Life Investment Management’s United Therapeutics UTHR Stock Holding History

New York Life Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$560K Sell
1,034
-4,576
-82% -$2.58M ﹤0.01% 745
2026
Q1 		$3.33M Buy
5,610
+1,818
+48% +$905K 0.03% 425
2025
Q4 		$1.85M Sell
3,792
-530
-12% -$247K 0.02% 530
2025
Q3 		$1.81M Sell
4,322
-263
-6% -$88.4K 0.02% 560
2025
Q2 		$1.32M Sell
4,585
-86
-2% -$25.7K 0.01% 599
2025
Q1 		$1.44M Buy
4,671
+10
+0.2% +$3.43K 0.01% 590
2024
Q4 		$1.64M Sell
4,661
-398
-8% -$146K 0.02% 578
2024
Q3 		$1.81M Sell
5,059
-1,004
-17% -$339K 0.02% 597
2024
Q2 		$1.93M Buy
6,063
+520
+9% +$138K 0.02% 562
2024
Q1 		$1.27M Sell
5,543
-101
-2% -$22.8K 0.01% 629
2023
Q4 		$1.24M Buy
5,644
+238
+4% +$54.9K 0.01% 620
2023
Q3 		$1.22M Buy
5,406
+2,573
+91% +$593K 0.01% 592
2023
Q2 		$625K Buy
+2,833
New +$628K 0.01% 638

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

New York Life Investment Management's UTHR Position: Q2 2026 in Review

New York Life Investment Management reduced its United Therapeutics (UTHR) stake by 82% in Q2 2026, selling an estimated $2.58M and leaving 1,034 shares worth $560K. The position accounts for ﹤0.01% of the portfolio, ranked #745.

New York Life Investment Management first reported a position in UTHR in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.33M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • New York Life Investment Management held 1,034 shares of United Therapeutics worth $560K as of Q2 2026.
  • New York Life Investment Management sold 4,576 United Therapeutics shares in Q2 2026, an estimated $2.58M.
  • United Therapeutics made up ﹤0.01% of New York Life Investment Management's portfolio in Q2 2026, its #745 holding.
  • New York Life Investment Management first reported a position in United Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • New York Life Investment Management's United Therapeutics position peaked at $3.33M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.